Method for restricting the necrosis area with roxytromycin while modeling coronary occlusion myocardial infarction in animals

FIELD: medicine, experimental cardiology.

SUBSTANCE: the present innovation deals with restricting the necrosis area in the course of experimental coronary occlusion myocardial infarction due to intragastric introduction of roxytromycin at the dosage of 30 mg/kg 15 min before coronary occlusion. The innovation provides significant decrease of the necrosis area due to cardioprotector action of roxytromycin.

EFFECT: higher efficiency.

1 ex, 1 tbl

 

The invention relates to medicine, namely to experimental pharmacology and cardiology.

The prototype of the present invention is: patent No. 2226101. "A method of restricting the zone of necrosis in the simulation coronacion myocardial infarction in animals with reduced antioxidant background.

The main disadvantage of this method is that azithromycin works only at low antioxidant background of the organism.

To address this shortcoming used macrolide antibiotic roxithromycin at a concentration of 30 mg/kg, which is valid for any antioxidant background of the body, effectively prevents the development of post-infarction pneumonia, and specifically accumulates in neutrophils and is transported to the area of aseptic inflammation, creating a high intracellular concentration, and, thus, limits the area of necrosis and increases survival of animals.

The technical result of the invention is a method of restricting the zone of necrosis invertirovannoi attack, including the use of roxithromycin related to macrolide antibiotic.

The technical result is achieved due to the fact that in order to limit the zone of necrosis is injected drug roxithromycin, which applies irrespective of antioxidant background of the organism. We used what was the dose of 30 mg/kg roxithromycin.

The method was carried out as follows.

Experiments carried out on white rats male Wistar weighing 350-450 g

Under General anesthesia (eleminal-sodium 50 mg/kg) was reproduced coronariography myocardial infarction (Achchan, 1979). 15 minutes before coronariography intragastrically injected roxithromycin at a dose of 30 mg/kg

Cardioprotective effect of study drug was assessed by comparison of the size of the zone of necrosis between the experimental group of animals without treatment and with treatment with investigational drug. And also assessed the impact of roxithromycin on mortality of laboratory animals in the first day after surgery. In the experience were not taken animals killed in the first 15 minutes after coronarography.

When the statistical processing of the data was calculated the mean value, the standard deviation value. The differences were considered significant at p<0,05.

Example

On white rats male Wistar simulated coronariography myocardial infarction. 15 minutes before coronariography intragastrically injected roxithromycin at a dose of 30 mg/kg of the Drug was administered once. After 24 hours was determined by the number of dead animals, and measured the amount of necrosis of the left ventricle when it planimetric definition.

To determine the objectives of the present invention were formed the following groups:

control (n=10);/p>

- roxithromycin 30 mg/kg (n=10).

The results are presented in table 1.

Table No. 1.

Values of mortality and percent necrosis of the left ventricle of rats in the simulation coronacion myocardial infarction on the 2nd day on the background of the application of roxithromycin.

(M±m;%, n=10)
Experimental group% necrosis% mortality
Control39,1±1,233,3±1,2
Roxithromycin 30 mg/kg26,9±1,8*12,5±1,5*
* at p<0,05 in comparison with the control group

Based on the data, follows that used macrolide antibiotic roxithromycin significantly improved the survival of animals in the first days after myocardial infarction compared with the control group. When this area of avascular necrosis of the left ventricle was significantly decreased while taking this drug.

Thus, the results indicate pronounced cardioprotective action of roxithromycin.

A method of restricting the zone of necrosis in the simulation coronacion myocardial infarction in Wistar rats, characterized by the fact that animals BBO is Yat macrolide drug roxithromycin at a dose of 30 mg/kg



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to pharmaceutical compositions containing inhibitor of cholesterol esters-transporting protein (CETP) and a water-insoluble additive increasing its concentration. As CETP inhibitor invention uses S-{2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl}-2-methylpropanethioate or a prodrug that forms in vivo S-{2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl}-thiol. A water-insoluble additive increasing the concentration of CETP inhibitor represents crospovidon. Indicated compositions show improved bioavailability in medium wherein they are used that allows using in methods for treatment of cardiovascular disorders.

EFFECT: improved and valuable pharmaceutical properties of compositions.

13 cl, 11 tbl, 5 dwg, 9 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes novel derivatives of triazolo[4,5-d]pyrimidine of the general formula (I): wherein R1 means (C3-C5)-alkyl that can be substituted with halogen atom; R2 means phenyl that can be substituted with fluorine atom; R3 and R4 are similar and mean hydroxy-group; R means XOH wherein X means -CH2, -OCH2CH2 or a bond, or their pharmaceutically acceptable salt or solvate of solvate of such salt under condition that when X means -CH2 or a bond then R1 doesn't mean propyl group; when X means -CH2 and R1 means -CH2CHCF3, butyl or pentyl groups then phenyl group at R2 must be substituted with fluorine atom; when X means -OCH2CH2 and R1 means propyl then phenyl group at R2 must be substituted with fluorine atom. Also, invention describes a pharmaceutical composition based on these compounds, method for their synthesis and novel intermediate compounds of the formula (II) , (V) and R-(R*,R*)-2,3-dihydroxybutanedioate (1:1) of compound of the formula (III): . Also, invention relates to a method for treatment of diseases mediated by P2T-receptors, such as myocardium infarction, prophylaxis or propagation of tumors and others.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions, improved method of synthesis.

15 cl, 9 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel hydrogenated azepino[4,3-b]indoles of the general formula (1): , their racemates, optical isomers, geometric isomers and their pharmaceutically acceptable salts and/or hydrates. In the general formula (1) a dotted line with accompanying unbroken line represents a simple or double bond; R1 and R2 represent independently of one another substitutes of amino-group chosen from hydrogen atom, possibly substituted (C1-C8)-alkyl possibly substituted with aryl, 5-6-membered azaheterocyclyl, (C1-C8)-alkoxycarbonyl, possibly substituted phenyl, possibly substituted carbonylamino- or thiocarbonylamino-group, substituted acyl, (C1-C8)-alkylsulfonyl, possibly substituted arylsulfonyl and wherein substitutes in indicated R1 and R2 are chosen independently from (C1-C8)-alkyl, halogen atoms, nitro-, carboxy-, alkoxy-group, aryl; Rin represents one or some similar or different substitutes of cyclic system chosen from hydrogen atom, (C1-C8)-alkyl, (C6-C10)-aryl, halogen atom, 5-6-membered azaheterocyclyl. Also, invention relates to methods for synthesis of these compounds, their using and pharmaceutical composition and libraries of compounds. Synthesized compounds possess neuroprotective, cognitive-stimulating and anti-histaminic properties and can be used in treatment of different neurological disorders, allergic and autoimmune diseases, for example, for memory improvement.

EFFECT: valuable medicinal and biological properties of compounds and pharmaceutical composition, improved method of synthesis.

25 cl, 2 tbl, 12 ex

FIELD: biologically active substances.

SUBSTANCE: invention relates to improved method of obtaining total amount of phenol acid including following steps: (a) multi-rooted sage is extracted with water and filtered; (b) filtrate is placed in polyamide column and washed with water to neutral reaction, wash water is removed, and polyamide column is eluted with weak aqueous alkali solution, and obtained fractions are connected; (c) alkali fractions obtained in step (b) are acidified and placed in absorption column with macroporous resin, column is washed to neutral state, wash water is removed, column is eluted with aqueous or anhydrous lower alcohol, eluent is collected, evaporated at reduced pressure to remove alcohol, and dried. Yield of final product exceeds 4% based on amount of crude drug and content of total amount of phenol acid exceeds 80%. Thus obtained total amount of phenol acid can be used as drug for prevention and treatment of brain vessel diseases.

EFFECT: enlarged resource of vegetable material for preparation of vascular drugs.

15 cl, 7 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to using inhibitor of absorption of sterol of the formula (VIII): or its pharmaceutically acceptable salts or solvates. This compound is used for preparing a medicinal agent that is used for decreasing the concentration of at least one sterol in plasma or tissues or their mixture of mammals wherein this sterol is not cholesterol or 5α-stanol. Also, invention relates to a method for decreasing the concentration of at least one sterol in plasma or tissue and involves administration to mammal a compound of the formula (VIII) in the dose 0.3-10 mg/1 kg of body mass per 24 h. Decreasing the content of content of indicated sterols in plasma or tissues provides prophylaxis or attenuation of such states as arteriosclerosis, risk of cardiovascular attack.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

19 cl, 6 tbl, 2 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to using compounds of (R,S)-2-arylpropionic acids of the formula (Ia) , and their (R)- and (S)-isomers as inhibitors of neutrophile (PMN leukocytes) chemotaxis induced by IL-8. These compounds elicit unexpected ability to inhibit effectively IL-8-induced chemotaxis and degranulation of neutrophiles being without significant effect on activity of cyclooxygenases. These compounds can be used in treatment of such diseases as psoriasis, ulcerated colitis, melanoma, chronic obstructive pulmonary disease, bulla pemphigus, rheumatic arthritis, idiopathic fibrosis, glomerulonephritis, and for prophylaxis and treatment of damages induced by ischemia and reperfusion.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

9 cl, 3 tbl, 43 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel indolyl-derivatives of the formula (I): and their pharmaceutically acceptable salts and esters wherein R1 means phenyl optionally substituted with from one to three substitutes chosen independently from halogen atom, (C1-C8)-alkyl, (C1-C8)-alkoxy-group and (C1-C8)-alkyl substituted with from one to three halogen atoms; R2 means hydrogen atom, (C1-C8)-alkyl; R3 means (C1-C8)-alkoxy-group; R4 means hydrogen atom; A means oxygen atom or sulfur atom; n = 1,2 or 3. Synthesized compounds possess agonistic activity with respect to PPARα- and/or PPARγ-receptors. Also, invention relates to methods for their synthesis, a pharmaceutical composition based on thereof and their using for preparing medicinal agents, and to a method for treatment and/or prophylaxis of diseases.

EFFECT: improved method of synthesis and treatment, valuable medicinal properties of compounds and pharmaceutical composition.

29 cl, 1 tbl, 7 sch, 17 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to pentafluorosulfanylbenzoylguanidines of the formulae (I) and (II) , wherein R1 means hydrogen atom, alkyl with 1-4 carbon atoms, F, Cl, Br or J; R2 means hydrogen atom or -O-phenyl that is unsubstituted or substituted with F, Cl, Br or J; each R3 and R4 means hydrogen atom, and to their pharmaceutically acceptable salts. Using compounds of formulae (I) and (II) provides inhibition of cellular sodium-proton pump and they can be used as anti-arrhythmic medicinal agents with cardioprotective effect for prophylaxis and treatment of infarction and stenocardia. Invention describes a method for synthesis of compounds, medicinal agent based on thereof and using in preparing medicinal agents.

EFFECT: improved method of synthesis and preparing, valuable medicinal properties of compounds.

10 cl, 6 ex

FIELD: medicine, pharmacology, phytotherapy.

SUBSTANCE: invention proposes two variants of agent possessing angiotropic effect. By the first variant agent comprises selenophospholipocoumarinoprotein representing two polypeptide A- and B-chains. The first chain consists of 20 amino acids and the second chain comprises residues of 29 amino acids joined by disulfide bridge by cysteine residues, and wherein selenium forms bonds between amino acids valine and leucine, between glutamic acids, and two diselenide bonds between A- and B-chain. Coumarins prepared by extraction from legumes, cereals and buckwheat plants are added to carboxyl groups of by-side acids - to residues of glutamic and/or aspartic acids, and/or to C-terminal carboxyl groups and wherein the molar ratio protein : phospholipid : selenium : coumarin = 1:1:8:4, respectively. By the second variant agent comprises selenophospholipocoumarinoprotein wherein flavonoids prepared by extraction of field horse-tail and knot-grass is added to carboxyl groups of by-side chains and/or terminal carbon atom and wherein the molar ratio protein : phospholipid : selenium : coumarin : flavonoids = 1:1:8:4:5, respectively. By the third variant agent comprises selenophospholipocumarinoprotein and calcium cations (Ca2+) and wherein the molar ratio protein : phospholipid : selenium : coumarin : Ca2+ : H2SiO42- = 1:1:8:4:8:4, respectively. Invention provides absence of adverse effect on body and promotes to activation of endothelial cells.

EFFECT: valuable biological and medicinal properties of agent.

3 cl, 3 ex

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition that comprises N-(chloro-4-morpholin-4-yl)-phenyl-N'-hydroxyimidoformamide and β-cyclodextrin sulfobutyl ester or its salt. Invention provides stability of a drug in storage, heating and light effect and shows practice in using also.

EFFECT: improved and valuable properties of pharmaceutical composition.

3 cl, 3 tbl, 7 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to compound of the general formula (I) wherein R1 and R2 mean independently of on another hydrogen atom (H) or fluorine atom (F); R3 means -CH3 or -CF3 ; Ar means structural formulae (a) or (b) Invention relates also to a pharmaceutical composition possessing the modulating activity with respect to progesterone receptor and containing compound of the formula (I), adjuvants, carriers and excipents. Compounds of the formula (I) are used in preparing a medicinal agent designated for selective modulation of processes in organ-targets mediated by progesterone receptor, such as uterus/breast and for selective activation of transcription of progesterone receptor isoform A as compared with transcription of progesterone receptor isoform B, selective enhancing processes mediated by progesterone receptor isoform A as compared with processes mediated by progesterone receptor isoform B and as a contraceptive. Invention provides a compound using as a medicinal agent in hormone-substitution therapy and for control of reproductive function.

EFFECT: valuable medicinal and biological properties of compound and pharmaceutical composition.

45 cl, 4 dwg, 5 tbl, 6 ex

FIELD: pharmacology, in particular composition and methods for obesity treatment.

SUBSTANCE: claimed composition contains lipase inhibitor, namely orlistat and koniac or glucomannan and pharmaceutically acceptable excipients.

EFFECT: composition preventing gastrointestinal disturbances associated with administration of lipase inhibitor orlistat.

35 cl, 10 ex, 3 dwg

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to compound represented by the structural formula: or its pharmaceutically acceptable salt wherein Z represents -(CH2)n-; double dotted line represents a double bond; n = 0-2; R1 and R2 are chosen independently from the group comprising hydrogen atom (H), alkyl with 1-6 carbon atoms; R3 means H, hydroxy-, alkoxy-group with 1-6 carbon atoms, -C(O)OR17 or alkyl with 1-6 carbon atoms; Het means monocyclic heteroaromatic group consisting of 6 atoms and comprising 5 carbon atoms and one heteroatom chosen from nitrogen atom (N) and wherein Het is bound through ring carbon atom and wherein Het-group has one substitute W chosen independently from the group comprising bromine atom (Br), heterocycloalkyl representing group consisting of 4 carbon atoms and one heteroatom chosen from N; heterocycloalkyl representing group consisting of 4 carbon atoms and one heteroatom chosen from N substituted with OH-substituted alkyl with 1-6 carbon atoms or =O; R21 -aryl-NH-; -C(=NOR17)R18; R21-aryl; R41-heteroaryl representing group consisting of 5-6 atoms comprising 3-5 carbon atoms and 1-4 heteroatoms chosen independently from the group: N, S and O; R8 and R10 are chosen independently from group comprising R1; R9 means H; R11 is chosen from group comprising R1 and -CH2OBn wherein Bn means benzyl; B means -(CH2)n4CR12=CR12a(CH2)n5; n4 and n5 mean independently 0; R12 and R12a are chosen independently from group comprising H, alkyl with 1-6 carbon atoms; X means -O-; Y means =O; R15 is absent as far as double dotted line mean a simple bond; R16 means lower alkyl with 1-6 carbon atoms; R17 and R18 are chosen independently from group comprising H, alkyl with 1-6 carbon atoms; R21 means 1-3 substituted chosen independently from group comprising hydrogen atom, -CN, -CF3, halogen atom, alkyl with 1-6 carbon atoms and so on; R22 is chosen independently from group comprising hydrogen atom; R24-alkyl with 1-10 carbon atoms; R25-aryl and so on; R23 is chosen independently from group comprising hydrogen atom, R24-alkyl with 1-10 carbon atoms, R25-aryl and -CH2OBn; R24 means 1-3 substitutes chosen independently from group comprising hydrogen atom, halogen atom, -OH, alkoxy-group with 1-6 carbon atoms; R25 means hydrogen atom; R41 means 1-4 substitutes chosen independently from group comprising hydrogen atom, alkyl with 1-6 carbon atoms and so on. Also, invention relates to a pharmaceutical composition possessing the inhibitory activity with respect to receptors activated by protease and comprising the effective dose of derivative of nor-seco-chimbacine of the formula (I) and a pharmaceutically acceptable excipient. Also, invention relates to methods for inhibition of thrombin and cannabinoid receptors comprising administration in mammal derivative of nor-seco-chimbacine of the formula (I) in the effective dose as active substance. Invention provides derivatives of nor-seco-chimbacine as antagonists of thrombin receptors.

EFFECT: valuable medicinal and biological properties of compounds and pharmaceutical composition.

8 cl, 1 tbl, 18 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a method for synthesis of discodermolid and its analogs of the formula (V): At the first step method involves the coupling reaction of ketone compound of the formula (I): with aldehyde compound of the formula (II): in the presence of dialkylboron halide or triphlate, amine base and polar organic solvent to yield β-hydroxyketone of the formula (III): at the second step method involves reduction of ketone compound synthesized at the first step by its treatment with boron hydride reagent in polar organic solvent medium and proton solvent to yield 1,3-diol of the formula (IV): at the third step method involves lactonization and removal of free acid-labile hydroxyl protective group of 1,3-diol synthesized at the second step by its treatment with hydrogen halide dissolved in polar solvent or mixture of solvents to yield the end compound of the formula (V) wherein R1 means (C1-C6)-alkyl; R2 means (C1-C6)-alkyl; R3 means hydrogen atom or acid-labile hydroxyl protective group; R3'' means acid-labile hydroxyl protective group; R4 means hydrogen atom or methyl group; X means oxygen atom (O) under condition that when X means O and R3 means acid-labile hydroxyl protective group of compound of the formula (I) then residue -X-R3 in compound of the formula (V) represents hydroxyl group (-OH). Also, invention relates to novel intermediate compounds of formulae (I), (III) and (IV) and to a method for synthesis of compound of the formula (I). Invention provides a new method for synthesis of the valuable compound discodermolid and its analogs with the satisfied yields.

EFFECT: improved method of synthesis.

16 cl, 4 ex

FIELD: pharmacy, chemical technology.

SUBSTANCE: invention relates to methods for preparing simvastatin of high purity degree from lovastatin by the following stages: (a) opening lactone ring in addition of lovastatin in reaction with amine for formation of amide; (b) protection of 1,3-diol moiety by a protecting group; (c) removal of 2-methylbutyryl group joined by ester bond through oxygen atom at position 8 in hexahydronaphthalene ring; (d) joining of 2,2-dimethylbutyrate group by formation of ester bond to hydroxyl at position 8; (e) removal of protecting group; (f) conversion of amide to acid salt, and lactone ring closure resulting to formation of simvastatin. Semi-synthetic statin is prepared from statin by carrying out the following steps: (a) opening lactone ring by reaction of statin with amine resulting to formation of amide; (b) protection of 1,3-diol moiety by using the protecting group; (c) removal of group R1 joined by ester bond through oxygen atom at position 8 in hexahydronaphthalene ring; (d) joining group R2 by formation of ester bond to hydroxyl at position 8; (e) removal of protecting group; (f) conversion of amide to acid salt, and (g) lactone ring closure with formation of semi-synthetic statin. Invention provides enhancing purity degree of the product.

EFFECT: improved preparing methods of statins.

17 cl, 19 ex

FIELD: medicine, pharmacology, biochemistry, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition that comprises a medicine orlistat and sucrose fatty acid ester wherein fatty acid moiety in fatty acid di-, tri- or tetra-ester means a mixture of two or some fatty acids. Also, invention relates to a method for treatment of obesity by using the claimed composition. Invention provides enhancing effectiveness of treatment.

EFFECT: enhanced and valuable properties of composition.

36 cl, 5 dwg, 7 tbl, 19 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to lyophilized composition comprising epotilone in the effective amount and mannitol or cyclodextrin. The second variant of the lyophilized composition involves epotilone and hydroxypropyl-beta-cyclodextrin. The preferable content of epotilone in the lyophilized composition is from 0.1% to 1.5%, and cyclodextrin - from 90% to 99% as measured for the total mass of solid components. Epotilone-containing lyophilized compositions can be used fro preparing an anti-tumor medicinal agent useful for parenteral administration and the lyophilized composition can be reduced preferably before administration directly. Epotilone-containing lyophilized compositions show improved indices of epotilone solubility and can retain stability for 24-36 months at temperature from 2°C to 30°C being without change of the solubility index.

EFFECT: improved and valuable properties of composition.

10 cl, 4 tbl, 14 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.

EFFECT: valuable medicinal properties of compounds.

21 cl, 1 dwg, 1 tbl, 6 ex

FIELD: medicine, cosmetology.

SUBSTANCE: one should apply acid composition onto patient's skin scar, moreover, this composition consists of the following ratio of components, weight%: alpha-hydroacid 0.1-70; gamma-lactone of 2,3-dehydro-L-gulonic acid 0.1-10; 1,2,3-propanetriol 1-10; strontium nitrate 0.5-10, water - the rest. Moreover, for steady penetration of this composition for desired depth against scars and surrounding skin one should treat them with alcoholic solution of beta-hydroxyacid for 3-7 d, and for improved regeneration one should lubricate it with an ointment supplemented with hydroxyacid for 7 d.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex

The invention relates to the field of medicine and for the application of cyclic ether (R)-3-hydroxybutyrate of formula (1) for the treatment of disease conditions mediated by free radicals, toxic agents, such as peptides and proteins, and genetic defects, harmful to the cell metabolism, insulin resistance or other defects in glucose metabolism or conditions that cause the defect, ischemia, head injury, and/or improve the efficiency of cells

FIELD: medicine, cosmetology.

SUBSTANCE: one should apply acid composition onto patient's skin scar, moreover, this composition consists of the following ratio of components, weight%: alpha-hydroacid 0.1-70; gamma-lactone of 2,3-dehydro-L-gulonic acid 0.1-10; 1,2,3-propanetriol 1-10; strontium nitrate 0.5-10, water - the rest. Moreover, for steady penetration of this composition for desired depth against scars and surrounding skin one should treat them with alcoholic solution of beta-hydroxyacid for 3-7 d, and for improved regeneration one should lubricate it with an ointment supplemented with hydroxyacid for 7 d.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex

Up!